The effects of mepyrapone (SU 4885) and some hypercholesterolaemic drugs on hepatic sterol and fatty acid oxidation.
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002331:Carnitine / Q000378:metabolism; D002417:Cattle; D002784:Cholesterol / Q000494:pharmacology*; D004336:Drug Antagonism; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D008099:Liver / Q000166:cytology / Q000201:enzymology; D008297:Male; D008797:Metyrapone / Q000494:pharmacology*; D051379:Mice; D008928:Mitochondria / Q000187:drug effects* / Q000378:metabolism*; D009206:Myocardium / Q000166:cytology; D009243:NAD / Q000378:metabolism; D010084:Oxidation-Reduction; D010088:Oxidoreductases / Q000378:metabolism*; D011335:Proadifen / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D013261:Sterols / Q000378:metabolism*; D014308:Triparanol / Q000494:pharmacology
D000924:Anticholesteremic Agents; D005227:Fatty Acids; D011725:Pyridines; D013261:Sterols; D009243:NAD; D014308:Triparanol; D002784:Cholesterol; D011335:Proadifen; D010088:Oxidoreductases; D002331:Carnitine; D008797:Metyrapone